Targeting a protein involved in aggressive B-cell lymphoma
Targeting c-Myc stability in c-Myc overexpressing large B-cell lymphoma
This study is looking at a type of aggressive lymphoma called double and triple-hit lymphomas to understand how a protein named TBL1X affects the disease, with the goal of finding better treatments to help patients live longer and healthier lives.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-11042777 on NIH RePORTER |
What this research studies
This research focuses on a specific type of aggressive B-cell lymphoma known as double and triple-hit lymphomas, which are characterized by the overexpression of certain proteins that lead to poor patient outcomes. The study aims to investigate the role of a protein called TBL1X in these lymphomas and explore new therapeutic strategies to improve survival rates. By understanding how TBL1X contributes to the disease, researchers hope to develop targeted treatments that could be more effective for patients with this challenging condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with double or triple-hit B-cell lymphomas who have high levels of c-Myc and BCL2 protein expression.
Not a fit: Patients with other types of lymphomas or those without the specific protein overexpression may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, more effective treatments for patients with aggressive B-cell lymphomas, potentially improving survival rates.
How similar studies have performed: Other research has shown promising results in targeting similar pathways in aggressive lymphomas, suggesting that this approach may be effective.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Alinari, Lapo — Ohio State University
- Study coordinator: Alinari, Lapo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.